HC Wainwright restated their buy rating on shares of Alimera Sciences, Inc. (NASDAQ:ALIM) in a research report released on Wednesday. The firm currently has a $5.00 price target on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued reports about the stock. Cowen Inc set a $3.00 price target on shares of Alimera Sciences and gave the stock a buy rating in a report on Tuesday, July 25th. Zacks Investment Research upgraded shares of Alimera Sciences from a sell rating to a hold rating in a report on Friday, September 8th. Finally, ValuEngine cut shares of Alimera Sciences from a hold rating to a sell rating in a report on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Alimera Sciences presently has a consensus rating of Hold and an average price target of $3.38.

Shares of Alimera Sciences (NASDAQ ALIM) opened at $1.26 on Wednesday. The company has a quick ratio of 4.65, a current ratio of 4.84 and a debt-to-equity ratio of -0.71. Alimera Sciences has a twelve month low of $1.04 and a twelve month high of $1.72.

A number of large investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. grew its holdings in Alimera Sciences by 24.3% in the second quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock worth $251,000 after purchasing an additional 35,200 shares during the period. KCG Holdings Inc. grew its holdings in shares of Alimera Sciences by 127.0% during the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 43,977 shares during the last quarter. JW Asset Management LLC grew its holdings in shares of Alimera Sciences by 15.6% during the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after buying an additional 130,000 shares during the last quarter. Finally, Stonepine Capital Management LLC grew its holdings in shares of Alimera Sciences by 158.2% during the third quarter. Stonepine Capital Management LLC now owns 477,226 shares of the biopharmaceutical company’s stock valued at $644,000 after buying an additional 292,399 shares during the last quarter. Institutional investors and hedge funds own 37.33% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Alimera Sciences, Inc. (ALIM) Earns Buy Rating from HC Wainwright” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.watchlistnews.com/alimera-sciences-inc-alim-earns-buy-rating-from-hc-wainwright-2/1725468.html.

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.